Home  >  News
you can get e-magazine links on WhatsApp.Click here
Pioma_Lactic
Biotechnology + Font Resize -

Caris Life, ESSA Pharma ink liquid biopsy profiling collaboration

Irving, Texas
Friday, October 8, 2021, 15:00 Hrs  [IST]

Caris Life Sciences, a molecular science company, and ESSA Pharma Inc., a clinical-stage pharmaceutical company, announced a Precision Development programme to support ESSA’s ongoing clinical development of EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) failing current standard-of-care therapies.

Under the terms of the agreement, Caris and ESSA will evaluate patient blood samples to assess genetic profiles utilizing Caris’ Whole Transcriptome Sequencing (WTS) and Whole Exome Sequencing (WES) platform. ESSA will utilize these liquid biopsies, including longitudinal data from serial samples, to better characterize the tumor biological profiles of patients in the ongoing monotherapy clinical trial of EPI-7386 in mCRPC patients.

“We are delighted to establish this collaboration with Caris,” said Dr. David. R. Parkinson, chief executive officer, ESSA Pharma Inc. “We believe the unique biological platform provided by Caris’ comprehensive WTS and WES profiling will provide important information at the individual patient level through a convenient blood-based test. This information may facilitate a more efficient development of EPI-7386 in patients with prostate cancer through the identification of relevant patient tumor biological subpopulations.”

“We are excited to partner with ESSA to expand the reach of Caris’ best-in-class liquid biopsy offering, assessing all 22,000 genes in both DNA and RNA, which are unique to an individual’s cancer,” said Brian Lamon, chief business officer at Caris Life Sciences. “Precision partnering means tailoring our capabilities to the needs of our partners to maximize the potential success for their therapeutic programs – and achieving our shared goal of delivering more precise therapeutic options to patients.”

EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor. EPI-7386 is currently being studied in a Phase 1 clinical trial (NCT04421222) in men with metastatic castration-resistant prostate cancer (“mCRPC”) whose tumors have progressed on current standard-of-care therapies. The Phase I clinical trial of EPI-7386 began in Q3 of 2020 following FDA allowance of the IND and Health Canada acceptance. The U.S. FDA has granted Fast Track designation to EPI-7386 for the treatment of adult male patients with mCRPC resistant to standard-of-care treatment. ESSA retains all rights to EPI-7386 worldwide.

Caris Life Sciences (Caris) is a molecular science company developing and delivering technologies to revolutionize healthcare.

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |